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ABSTRACT
Over the last decades, the introduction of several new
agents into clinical practice has significantly improved
disease control and obtained some, albeit rare, survival
benefits in metastatic breast cancer (MBC). Despite
these results, the choice of treatment for the majority of
patients is still empirically based, since the only two pre-
dictive factors with level 1 evidence for clinical use are
hormonal receptor status for endocrine therapy and
HER-2 status for trastuzumab therapy.
Important improvements in the endocrine therapy of
both pre- and postmenopausal women with hormone-
responsive disease have been achieved. For premeno-
pausal women, ovarian function suppression with
luteinizing hormone-releasing hormone analogs com-
bined with tamoxifen has become the standard treat-
ment, although aromatase inhibitors plus ovarian function
suppression are under evaluation. In postmenopausal pa-
tients, aromatase inhibitors have proved to be superior to
standard endocrine therapies in either first- or second-line
treatment and a novel antiestrogen compound, fulves-
trant, has been introduced in clinical practice.
Chemotherapy remains the treatment of choice for hor-
mone unresponsive or resistant patients. Anthracyclines
and taxanes have been used either alone or in combination
as first-line chemotherapy, but with the more frequent use
of these agents in the adjuvant setting, new standards are
needed for first-line chemotherapy, and new and more ef-
ficacious treatments are required.
In the subgroup of patients with tumors that overex-
press HER-2, the use of trastuzumab alone or in combi-
nation with chemotherapy has modified the natural
history of these tumors, even if only about one out of two
patients obtains a clinical response.
In this review we summarize the main achievements
and the currently available treatment options for pa-
tients with MBC. The Oncologist 2007;12:253–270
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INTRODUCTION
Clinical research in the pregenomic era has achieved impor-
tant advances in breast cancer (BC) treatment using empir-
ical methods to compare different therapies. The only
accepted predictive factors are hormonal receptor (HR) sta-
tus to select endocrine therapy (ET) and, more recently, hu-
man epidermal growth factor receptor-2 (HER-2) status for
the use of trastuzumab [1]. In spite of adequate primary
therapy, many patients with apparently localized disease
harbor subclinical micrometastases that may grow into clin-
ically relevant macrometastases later on. In addition, 6%–
10% of newly diagnosed BC patients have locally advanced
or metastatic disease. Metastatic breast cancer (MBC) pa-
tients have a median survival period of 2–3 years [2], with
few of them (2%) surviving 20 years after the diagnosis of
metastasis [3]. This occurs despite the discovery of and in-
corporation into clinical practice of numerous new agents
(e.g., taxanes, vinorelbine, capecitabine, gemcitabine, tras-
tuzumab, aromatase inhibitors [AIs], and bisphosphonates)
that can palliate the disease [4] and, more rarely, increase
overall survival (OS) [5–12]. Therefore, for the majority of
patients with MBC, “cure” is not the goal of treatment; in-
stead, more conservative treatments are preferred to obtain
maximum control of symptoms, prevent serious complica-
tions, and prolong life with minimal toxicities and disrup-
tion of quality of life (QoL).
Following the assessment of the extent of the disease,
patients can be classified as “low risk” and “moderate/high
risk,” according to the parameters shown in Table 1.
The observation that a higher objective response rate
(ORR) and longer time to treatment progression (TTP) do
not always translate into detectable OS advantages might be
related to several factors: the pattern of BC growth, the
small size of the majority of trials [13], and the study de-
signs incorporating a crossover to the investigational drug
or regimen. The most important advances and the new stan-
dards of care for endocrine, cytotoxic, and biological ther-
apies in the era of “empirical oncology” are summarized in
this review.
Endocrine Therapy
Since the observation made by Sir Beatson [14] more than
100 years ago that oophorectomy in premenopausal women
could induce tumor regression, ET has been extensively
used in the treatment of BC in all stages. The suppression of
tumor growth can be obtained by: (a) reducing estrogen (E)
levels with surgical, radiation, or chemical ovarian ablation
(OA) in premenopausal women, or with AIs in postmeno-
pausal women; (b) blocking the interaction between E and
the estrogen receptor (ER) with selective ER modulators
(SERMs); or (c) destroying the ER with selective ER down-
regulators (SERDs). In MBC patients, the presence of HRs
[15, 16] and their quantitative levels [16, 17] are strongly
predictive of hormone responsiveness [18, 19]. However,
about 30% of patients do not respond to ET even if both
HRs (ER and the progesterone receptor [PgR]) are positive
(de novo resistance), and a considerable percentage of ini-
tially responsive patients become resistant to it (acquired
resistance).
Postmenopausal Patients
Tamoxifen, a nonsteroidal antiestrogen with partial agonist
activity, began to be used in clinical trials for MBC in 1971
and has remained ”the gold standard” for first-line ET for
almost 30 years. The second-line drugs were mainly pro-
gestins and the first-generation AIs, aminoglutethimide
(AG) with corticosteroid support. Recently, new hormonal
agents have been developed, particularly novel AIs and an-
tiestrogens.
AIs
Second-Line
The second- and third-generation AIs are more selective,
better tolerated, and more potent than AG. Third-generation
AIs are classified into two types, based on their chemical
structure and mechanism of action: nonsteroidal/reversible
(anastrozole, letrozole, and vorozole) and steroidal/irre-
versible (exemestane). The first randomized trials using
these agents were conducted in postmenopausal women
who had progressed on tamoxifen or relapsed within 12
months after stopping the drug as adjuvant therapy, and all
four agents were compared with megestrol acetate (MA).
The results of these trials [20–25] are summarized in Table
2.
Vorozole, although as effective as MA and better toler-
ated, was discontinued from clinical development [26].
Letrozole and vorozole were also compared with AG (500
mg/day) with corticosteroid support in a similar patient
population [27, 28], and the main outcomes are shown in
Table 2. Based on the results of these studies, third-gener-
ation AIs became the standard second-line ET for post-
menopausal women with HR-positive tumors.
Only one randomized open-label multicenter trial has
directly compared two third-generation AIs in postmeno-
pausal patients with MBC considered refractory to anties-
trogens [29]. A higher ORR was obtained with letrozole
than with anastrozole in HR-positive patients and in those
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with visceral or soft tissue metastasis, without significant
differences in TTP, time to treatment failure (TTF), or OS.
Unfortunately, this study was not double blind, was indus-
try sponsored, and the HR status was unknown in 52% of
patients. AIs have also been evaluated as third-line therapy,
and a lack of cross-resistance between them has been re-
ported [30, 31]; the best sequence is still unknown [32].
First-Line
Based on the positive results obtained in second-line ET,
anastrozole, letrozole, and exemestane were compared with
tamoxifen as first-line therapy in large, phase III, random-
ized, multicenter trials enrolling postmenopausal women
with HR-positive or unknown MBC. Adjuvant tamoxifen
had to be completed at least 6 months previously. Anastro-
zole was evaluated in two identically designed studies, one
conducted in the U.S./Canada [33, 34] and the other in Eu-
rope and the rest of the world [35]. No significant difference
in ORR was reported in either study, while a significantly
longer median TTP was observed only in the first one [33],
in which the percentage of patients with HR-positive tu-
mors was higher. Similarly, a statistically significant longer
TTP favoring anastrozole in HR-positive patients was ob-
tained pooling the data of the two studies [36]. Letrozole
was superior to tamoxifen in a double-blind, double-
dummy, randomized trial in which a crossover at progres-
sive disease (PD) was included in the design [37, 38]. A
significantly longer TTP and TTF and higher ORR and clin-
ical benefit (CB) rate in the letrozole arm were observed in
the entire population and in different subgroups selected ac-
cording to previous adjuvant treatment with tamoxifen, HR
status (positive or unknown), and dominant metastatic site.
A higher ORR and a significantly longer progression-free
survival (PFS) duration with exemestane in comparison
with tamoxifen were reported [39].
The most important findings of each trial [33–39] are re-
ported in Figure 1. The AIs were well tolerated, with better
toxicity profiles than with tamoxifen. Following the publi-
cation of these results, AIs became the new gold standard
first-line ET in postmenopausal MBC patients.
A meta-analysis of 23 published randomized controlled
trials comparing several generations of AIs with standard
ET (tamoxifen or progestagens) in MBC has recently
shown a survival benefit with third-generation AIs as first-
line as well as second- and subsequent-line treatment [40].
Novel Antiestrogens
Several novel antiestrogen compounds, with a lower ago-
nist profile on breast and gynecologic tissues in comparison
with tamoxifen, have been developed. There are two major
groups of agents: (a) the SERMs, further divided into tri-
phenylethylenes, of which the parent compound is tamox-
Table 1. Metastatic breast cancer: Risk evaluation according to factors that affect prognosis
Factors predicting the risk for recurrence Low risk Moderate/high risk
Hormone receptor status Positive Negative
HER-2 expression status Negative Positive
Disease-free interval 2 years 2 years
Metastatic burden Limited Extensive
Metastatic sites Soft tissues, Bones Viscera
Vital organ involvement No Yes
Table 2. Randomized trials of third-generation AIs as second-line therapy in postmenopausal women after tamoxifen
failure (n  3,647)
Number of trials showing superior outcome for
new AI
OS TTF TTP RR
4 trials of a new AI challenging MA (n  2,536) 21–26, 197 2 (A/E) 2 (L1/L2/E) 1 (E) 1 (L1)
2 trials of a new AI challenging AG (n  1,111) 27, 28 1 (L1) 2 (L1 /V) 1 (L1) 0
Abbreviations: A, anastrozole; AG, aminoglutethimide; AI, aromatase inhibitor; E, exemestane; L1, letrozole 2.5 mg; L2,
letrozole 0.5 mg; MA, megestrol acetate; OS, overall survival; RR, response rate; TTF, time to treatment failure; TTP, time
to progression.
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ifen, and benzothiophenes, with a “fixed ring” structure;
and (b) the SERDs, also called “pure antiestrogens,” which
can be either steroidal or nonsteroidal. Among the latter,
fulvestrant has obtained the most interesting results. This
pure antiestrogen has a peculiar mechanism of action, down-
regulating the ER and reducing the PgR content of the tumor.
Second-Line
Fulvestrant was compared with anastrozole in two random-
ized phase III trials enrolling postmenopausal patients with
locally advanced BC or MBC who had progressed after re-
ceiving tamoxifen as adjuvant or first-line therapy. In a
combined analysis of both studies [41], there was no statis-
tically significant difference between the two arms for all
clinical outcomes, and, for the first time, an antiestrogen
showed activity in patients refractory to tamoxifen.
First-Line
In postmenopausal patients with untreated MBC and HR-
positive or unknown tumors, fulvestrant and tamoxifen
have been compared in a large, double-blind, randomized
trial. No significant differences in outcomes have been re-
ported, but the TTF was statistically shorter in the fulves-
trant group (5.9 months versus 7.8 months, respectively;
p  .026) [42]. A higher incidence of hot flushes was ob-
served in patients treated with tamoxifen. These results
could partially be explained by the pharmacokinetics of ful-
vestrant, because a monthly injection of fulvestrant, 250
mg, may take 3–6 months to produce steady-state plasma
levels [42].
In conclusion, four categories of postmenopausal pa-
tients can be considered when selecting the sequence of ET
agents in MBC: (a) ET naı¨ve; (b) tamoxifen sensitive, if
there was prior tamoxifen exposure but interval to the ap-
pearance of metastatic lesions was 1 year; (c) tamoxifen
resistant, if there was prior tamoxifen exposure but the in-
terval to relapse was 1 year; and (d) progressive on non-
steroidal AIs [43]. The first two categories can be viewed as
one group in terms of therapy options, and for these patients
the nonsteroidal or steroidal AIs are the first choice. For pa-
tients defined as tamoxifen resistant without previous ex-
posure to AIs, these drugs or fulvestrant can be selected. In
patients progressing on nonsteroidal AIs, the best hormonal
agent—tamoxifen, fulvestrant, or exemestane—has not yet
been defined. Indeed, a combined analysis of two interna-
tional, randomized, double-blind trials has shown that 48%
of patients showed a CB with tamoxifen administered after
first-line anastrozole [44], although the opposite sequence
was shown to be superior in a small, randomized, double-
blind first-line crossover trial [45]. In phase II trials, fulves-
trant after an AI or an AI and tamoxifen has been shown to
have efficacy with an acceptable toxicity profile [46–48]. It
is hoped that a better understanding of the mechanisms of
resistance to antiestrogens and to AIs and how to prevent or
delay resistance, together with the possibility of defining
the subgroups of patients responsive to specific agents, will
help us to select the best treatment approach for individual
patients.
PREMENOPAUSAL PATIENTS
For premenopausal patients, endocrine options include oo-
phorectomy, ovarian irradiation, or the use of luteinizing
hormone-releasing hormone (LHRH) analogs, tamoxifen,
or a combination of both. Surgical or radiation OA pro-
duced an ORR ranging from 30% in unselected patients
[49, 50] to 79% in those with ER-positive tumors [51, 52];
comparative studies have shown similar results with the
two procedures [53]. In the late 1970s and early 1980s, it
was demonstrated that tamoxifen was also active in pre-
menopausal women [54]. In three small trials [50, 55, 56]
and in a meta-analysis of these studies [57], tamoxifen was
as effective as OA as first-line treatment for ER-positive
MBC. In a limited number of patients, both treatments were
effective as second-line therapy at progression, but a signif-
icantly higher ORR occurred with OA. By the late 1980s
and early 1990s, tamoxifen became the standard ET for pre-
menopausal women with MBC, followed at progression by
surgical or radiation OA and, subsequently, by the other
hormonal agents used for postmenopausal women. In the
early 1990s, however, LHRH analogs became available,
and these agents are able to produce medical OA in pre-
menopausal women, potentially reversible upon discontin-
uation of therapy. The tolerance profile of these drugs is
good, and the most common side effects are hot flushes and
tumor flare reactions. The largest phase III trial comparing
Figure 1. Aromatase inhibitors (AIs) as first-line endocrine
therapy in postmenopausal patients with metastatic breast can-
cer. Abbreviations: NA, not available; OS, overall survival;
RR, response rate; Tam, tamoxifen; TE, too early; TTF, time to
treatment failure; TTP, time to progression.
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surgical OA with goserelin did not find differences in PFS,
OS, or the ORR in 136 premenopausal patients with HR-
positive MBC [58]. A combination of an LHRH analog and
tamoxifen to obtain “complete estrogen blockade” was
compared with an LHRH analog alone in three small, ran-
domized studies in pre- and perimenopausal patients with
ER-positive or unknown MBC [59–61]. A meta-analysis
of these trials evaluating 506 patients showed a higher
ORR, longer PFS time, and longer OS time in women
treated with complete estrogen blockade. There are, how-
ever, some caveats about these data: (a) the number of pa-
tients enrolled in each study was small; (b) the ER positivity
of tumors was confirmed in only 62% of patients; (c) the
patients received various previous adjuvant treatments; (d)
in three trials there was no formal crossover to tamoxifen as
second-line therapy in patients treated with an LHRH ana-
log alone; (e) the toxicity profile was not well reported; and
(f) QoL evaluation was lacking. Nonetheless, the combina-
tion of an LHRH analog and tamoxifen is now accepted as
the treatment of choice in premenopausal patients with
MBC. A new promising option could be the combination of
an LHRH analog and an AI, but, presently, few data are
available [62–66].
CHEMOTHERAPY
Chemotherapy (CT) is currently the only therapeutic option
for women with HER-2–negative, endocrine-resistant
MBC, or for women with extensive visceral localizations or
life-threatening disease. The most used drugs are anthracy-
clines, taxanes, alkylating agents, antimetabolites, and
vinca-alkaloids. Used as single agents, they produce an
ORR of 20%– 80% [67– 69], whereas the combinations
seem to increase the ORR but not the percentage of com-
plete responses (CRs). Furthermore, the majority of CRs
are short lived [3, 70]. An interesting correlation between
CR and long-term disease-free survival has been reported in
studies using both standard-dose and high-dose CT [3, 71,
72]. According to these studies, it appears that a CR is nec-
essary but not sufficient to predict long-term PFS; however,
other authors consider CR a valid surrogate endpoint for OS
[73].
Pre-Taxane Era
In the pre-taxane era, several combination regimens were
developed, and these yielded higher ORRs, sometimes
longer TTP, and even longer OS times in comparison with
monochemotherapies [74–83]. In a meta-analysis of ran-
domized trials, anthracycline-containing regimens were
found to be superior to a combination of cyclophospha-
mide, methotrexate, and 5-fluorouracil (CMF) [13]. Fur-
thermore, no significant differences were observed
between doxorubicin and epirubicin at equivalent doses,
but epirubicin was less toxic in a meta-analysis of compar-
ative randomized trials [84].
Taxane Era
Anthracycline-Naı¨ve or Minimally Exposed Patients
Taxanes as Monochemotherapy. Paclitaxel and docetaxel
have both been compared with doxorubicin in the first-line
treatment of MBC. In one study, docetaxel produced a
higher ORR than doxorubicin, but no difference in TTP or
OS time [85]; in a three-arm study, paclitaxel was com-
pared with doxorubicin and with the combination of the two
drugs, with no statistically significant differences between
the two single agents, although a higher ORR and longer
TTP was shown for the combination [86]. In another study,
doxorubicin was superior to paclitaxel in terms of ORR and
TTP [87]. A significantly longer OS time after adjustment
for prognostic factors, without differences in the ORR and
TTP, was obtained with paclitaxel in comparison with
CMF plus prednisone in untreated patients [6], but this ad-
vantage could be attributed to a better sequence of treat-
ments, because about 40% of the patients received
anthracyclines at progression. The criticisms of most of
these trials are summarized in Table 3, and their results can
be found in Table 4.
Taxanes as Combination Therapy. Several studies have
compared combinations of taxanes and anthracyclines with
standard anthracycline-based regimens as first-line treat-
ment for anthracycline-untreated or minimally exposed
MBC patients. Paclitaxel plus doxorubicin yielded a signif-
icantly greater ORR, longer TTP, and longer OS time in
comparison with a combination of fluorouracil, doxorubi-
cin, and cyclophosphamide (FAC), but with a significantly
higher incidence of grade 3 or 4 neutropenia. However,
QoL was similar with the two regimens [10]. The weakness
of this study is to be found in the suboptimal dose of the
FAC regimen chosen and the fact that only one fourth of the
patients treated with this regimen received taxanes at pro-
gression. No significant differences were observed in three
other large trials comparing a combination of paclitaxel and
doxorubicin [88] or paclitaxel and epirubicin [89, 90] with
standard regimens containing doxorubicin/epirubicin and
cyclophosphamide.
Docetaxel in combination with doxorubicin (AD)
[91] or with doxorubicin and cyclophosphamide (TAC)
[92] has been compared with standard regimens such as
doxorubicin and cyclophosphamide (AC) or FAC. A
higher ORR was observed in both trials, but only in one
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[91] did this translate into a longer TTP. A significantly
higher incidence of grade 3 or 4 hematological and non-
hematological toxicities was reported with the TAC reg-
imen, including more cardiotoxicity. Similar results,
with a significantly longer OS time but higher incidence
of febrile neutropenia and two toxic deaths in the do-
cetaxel arm, were reported in a trial comparing AD with
FAC as first-line CT in MBC patients [12]. The lack of
minimal crossover reports in the taxane trials does not
enable a definite conclusion to be drawn regarding the
value of combination CT versus the sequential use of sin-
gle agents. These studies are summarized in Table 5. An
additional trial that compared a combination of docetaxel
or paclitaxel with doxorubicin as first-line metastatic CT
did not show any significant difference in ORR, PFS, or
OS between the two arms [93]. Furthermore, in a recent
meta-analysis of taxanes alone or in combination with
anthracyclines as first-line CT for MBC, single-agent an-
thracycline therapy was significantly better than single-
agent taxane therapy in terms of PFS, but not in terms of
Table 4. Randomized trials of single-agent taxanes in metastatic breast cancer patients with minimal or no previous
anthracycline exposure
Regimen n of patients
RR
(p-value)
RR at crossover
(%)
TTP
(p-value)
OS (months)
(p-value)
Docetaxel 326 47.8% No 26 weeks 15
Doxorubicin [85] 33.3% 21 weeks 14
(.008) (.45) (.38)
Paclitaxel 739 34% 22 6.3 monthsa 22.5
Doxorubicin 36% 20 6.0 months 19.1
Paclitaxel/doxorubicin [86] 47% 8.2 months 22.4
(.007) (.002) (NS)
Paclitaxel 331 25% 16% 3.9 monthsb 15.6
Doxorubicin [87] 41% 30% 7.5 months 18.3
(.003) (.001) (.38)
Paclitaxel 209 29% No 5.3 months 17.3
CMFp 6 35% 6.4 months 13.9
(.37) (.25) (.068)
aTime to treatment failure.
bProgression-free survival.
Abbreviations: C, cyclophosphamide; F, 5-fluorouracil; M, methotrexate; NS, not significant; OS, overall survival; p,
prednisone; RR, response rate; TTP, time to progression.
Table 3. Overview of randomized phase III trials of taxanes in metastatic breast cancer patients with minimal or no
previous anthracycline exposure and after anthracycline failure
No (or minimal) anthracycline exposure Anthracyline failure
Most trials are underpowered Most trials are underpowered
Few trials with crossover design No trials with crossover design
One trial compares combination with single agent
Docetaxel trials: greater ORR in all trials, longer TTP in
most trials, longer OS in 1 trial 12, 85, 91, 92
Docetaxel trials: greater ORR and longer TTP in
all trials, and longer OS in two trials 9, 11
Paclitaxel trials: mixed results for ORR and TTP, longer
OS in 1 trial 10, 86–90, 93
Paclitaxel trials: longer TTP and OS 100, 101
Greater toxicity with combinations Greater toxicity with combinations
Abbreviations: ORR, overall response rate; OS, overall survival; TTP, time to progression.
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OS; taxanes in combinations, moreover, resulted in a sig-
nificantly better ORR than with anthracycline-contain-
ing combinations, but were only marginally better in
terms of PFS and not in terms of OS [94].
Anthracycline Resistant or Refractory Patients
The common use of anthracycline-based regimens in the
adjuvant setting has increased the likelihood of anthracy-
cline-resistant MBC. In phase II trials, docetaxel as a single
agent has produced a high ORR [95, 96] and, compared
with non–anthracyclines-based regimens in a similar pa-
tient population, has shown a higher ORR with a signifi-
cantly longer TTP in one trial [97], and also a significantly
longer OS time in another one [7]. Although crossover had
not been planned in those studies, docetaxel can be consid-
ered the standard of care as monotherapy for anthracycline
resistant or refractory patients, particularly because there
are no studies with paclitaxel as monotherapy.
Taxane-based combinations without anthracyclines
have also been evaluated in this population. In a phase III
randomized multicenter trial, a combination of docetaxel
plus capecitabine was compared with single-agent do-
cetaxel [9]. The combination achieved a higher ORR and
longer median TTP, and also a significantly longer OS time
of 3 months. QoL was similar, while toxicities in the two
treatment arms were different. Neutropenic fever/sepsis,
myalgia, and arthralgia were more common in the do-
cetaxel arm, whilst gastrointestinal side effects and hand–
foot syndrome occurred more frequently in the combination
arm. An interesting aspect of this study relates to the pre-
clinical evidence of synergy between docetaxel and cape-
citabine [98, 99], even if the nature of this interaction has
yet to be fully defined. In another large trial with a similar
design, three-weekly paclitaxel was compared with a com-
bination of gemcitabine and paclitaxel that yielded superior
results in terms of ORR, TTP [100], and OS [101]. The lack
of a planned crossover does not allow for a comparison be-
tween the combination and the sequential approach in these
two trials; however, the U.S. Food and Drug Administra-
tion (FDA) has approved both combination regimens for
the first-line treatment of MBC patients pretreated with an-
thracyclines [102]. In anthracycline-pretreated MBC pa-
Table 5. Randomized trials of anthracycline/taxane combinations versus polychemotherapy in metastatic breast cancer
patients with minimal or no previous anthracycline exposure
Regimen n of patients
RR
(p-value)
RR at crossover
(%)
TTP
(p-value) OS (p-value)
Docetaxel-based
AD 429 59% No 37.3 weeks 22.5 weeks
AC 91 47% 31.9 weeks 21.7 weeks
(.009) (.014) (.26)
DAC 484 55% No 31 weeks 21 months
FAC 92 44% 29 weeks 22 months
(.023) (.51) (.93)
AD 216 58% No 8.0 months 22.6 months
FAC 12 37% 6.6 monthsa 16.1 months
(.003) (.004) (.019)
Paclitaxel-based
AP 267 68% No 8.3 months 23.3 months
FAC 10 55% 6.2 months 18.3 months
(.032) (.034) (.013)
AP 275 58% No 6.0 months 20.6 months
AC 88 54% 6.0 months 20.5 months
(0.51) (.65) (0.49)
EP 705 65% No 7.0 months 13 months
EC 90 55% 7.1 months 14 months
(.015) (.41) (.8)
EP 560 46% 39 weeks NR
EC 89 41% 33 weeks
(.089)
aThe primary endpoint was progression-free survival.
Abbreviations: A, doxorubicin; D, docetaxel; E, epirubicin; F, 5-fluorouracil; C, cyclophosphamide; P, paclitaxel; NR, not
reported; OS, overall survival; RR, response rate; TTP, time to progression.
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tients, no differences in ORR, duration of response, median
TTF, or PFS were observed in a phase III trial comparing
docetaxel plus gemcitabine with docetaxel plus capecita-
bine. However, treatment discontinuation due to adverse
events was more frequently reported in the capecitabine
combination arm (28% versus 13%; p .014), which could
be related to the quite high doses used for both drugs [103].
Another phase III trial comparing docetaxel with vi-
norelbine plus 5-fluorouracil in 86 anthracycline-refractory
patients failed to show any difference in TTP or OS, but do-
cetaxel was less toxic, except for neutropenia [104].
ABI-007 (Abraxane®; AstraZeneca, Wilmington, DE)
is a novel, biologically interactive, albumin-bound pacli-
taxel in a nanometer particle, free of solvents, developed to
avoid toxicities associated with polyethylated castor oil.
The drug was compared with standard paclitaxel in patients
with MBC, candidates for single-agent paclitaxel in a phase
III study. About 50% of patients had previously received
anthracycline-based therapy for metastatic disease. ABI-
007 was associated with a significantly higher response rate
compared with standard paclitaxel (33% versus 19%; p 
.001) and longer TTP (23.0 versus 16.9 weeks; hazard ra-
tio  0.75; p  .006). Interestingly, a significantly longer
OS time was observed in the subgroup of patients who re-
ceived ABI-007, compared with standard paclitaxel, as sec-
ond-line or greater therapy (56.4 versus 46.7 weeks; p 
.024). The incidence of grade 4 neutropenia was signifi-
cantly lower for ABI-007 (9% versus 22%; p  .001), de-
spite a 49% higher paclitaxel dose; however, grade 3
sensory neuropathy was more common in the ABI-007 arm
(10% versus 2%; p  .001), albeit easily managed and rap-
idly improving (median 22 days). No hypersensitivity reac-
tions occurred with ABI-007 despite the absence of
premedication and shorter administration time [105].
Which Taxane and Which Dose?
In the TAX-311 study, docetaxel and paclitaxel, both ad-
ministered every 3 weeks in MBC patients resistant to an-
thracyclines, were compared head to head [11]. In this
industry-sponsored trial, the median TTP and OS time were
significantly longer in the docetaxel arm, but the ORR, al-
though higher, did not reach statistical significance. These
advantages were, however, associated with greater hemato-
logical and nonhematological toxicities and with four treat-
ment-related deaths.
Both taxanes can be administered every 3 weeks and
weekly. For paclitaxel, several prospective studies have
compared different doses and different infusion times, but
none has so far shown a clear advantage over the registered
one (175 mg/m2 as a 3-hour infusion) given every 3 weeks
[106–109]. General consensus exists for the dose and infu-
sion time of docetaxel (100 mg/m2 in 1 hour) approved for
the treatment of MBC in the U.S. and in Europe. Recently,
three different doses of docetaxel (60, 75, and 100 mg/m2)
have been evaluated in pretreated MBC patients [110], and
although significantly higher ORRs were obtained with
high doses, no difference in median TTP and OS among the
three arms was reported in the intention-to-treat analysis.
Most hematologic and nonhematologic toxicities were re-
lated to increasing doses, with grade 3–4 neutropenia and
febrile neutropenia occurring in a higher percentage of pa-
tients with the highest dose.
The weekly administration of taxanes has received
growing interest as a way to increase efficacy and/or de-
crease toxicity. The only advantage reported for weekly do-
cetaxel has been a reduction in myelosuppression. In
contrast, the mechanism of action of weekly paclitaxel
seems different [111], and recently, in a phase III random-
ized trial comparing weekly with every-3-week paclitaxel
with and without trastuzumab in HER-2–negative or over-
expressing MBC patients, a higher ORR and longer TTP
were reported with the weekly schedule [112].
Of note, preclinical and clinical data have shown that
crossresistance between the two taxanes is only partial;
consequently, their sequential use a few months apart is
possible, in particular for initially responsive patients [113,
114].
Anthracycline- and Taxane-Resistant Patients
No standard of care exists after failure of both anthracycline
and taxane treatment, and options for patients in this situa-
tion are limited. The most common treatments are chosen in
view of their manageable toxicity profiles and reasonable
efficacy, because no randomized study has so far demon-
strated a benefit in OS after second-line CT [70].
Capecitabine is the first oral fluoropyrimidine approved
by the FDA for the treatment of MBC patients whose prior
anthracycline- and taxane-based CT has failed. At least five
phase II trials enrolling 547 anthracycline- and/or taxane-
pretreated patients have been reported. Capecitabine as a
single agent produced an ORR of 15%–29% and a median
OS duration of 9.4–15.2 months [115–119]. The drug alone
or in combination has also been evaluated in anthracycline-
pretreated and untreated MBC patients in phase II trials
[120–123].
Intravenous vinorelbine has shown a variable ORR
(10%–20%) after anthracycline or taxane failure [124,
125], with a low incidence of nonhematological toxicities.
An oral formulation of vinorelbine has been evaluated re-
cently as first-line chemotherapy for MBC, and the results
suggest that it is an effective and well-tolerated agent, of-
fering an alternative to the i.v. route [126]. Vinorelbine also
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performed better than oxaliplatin in PFS and OS in a phase
III trial [127]. Irinotecan given either weekly or every 3
weeks showed some response in this subset of patients
[128]. More recently, epothilones, a new class of antitubu-
lin agents that lacks crossresistance with the taxanes, have
been developed in the metastatic setting, with promising re-
sults [129, 130].
Pegylated liposomal doxorubicin has also been tested in
MBC with encouraging results and less cardiotoxicity. In a
randomized phase III trial, pegylated liposomal doxorubi-
cin HCL (Caelyx®; Schering-Plough Corporation, Ken-
ilworth, NJ) showed similar results in terms of ORR, PFS,
and OS when compared with doxorubicin as first-line CT,
with significantly lower cardiotoxicity but a higher inci-
dence of palmar–plantar erythrodysesthesia [131]. Similar
results were seen with nonpegylated liposomal doxorubicin
(Myocet®; Sopherion Therapeutics, Inc., Princeton, NJ) in
comparison with doxorubicin as a single agent or in com-
bination with cyclophosphamide [132, 133]. However, in a
randomized phase III trial in taxane-refractory MBC pa-
tients, pegylated liposomal doxorubicin yielded a signifi-
cantly longer PFS time than the comparator (vinorelbine or
mitomycin plus vinblastine) in the subgroup of anthracy-
cline-naı¨ve patients [134].
Combination Versus Sequential CT
The question of “optimal” modality of administering anti-
tumor agents, sequentially or in combination, remains con-
troversial, and it is doubtful that either strategy is
appropriate for all patients.
The ideal combination regimen should include active
and non-crossresistant single agents with preclinical evi-
dence of synergy and nonoverlapping side effects. How-
ever, all three criteria are rarely met and, consequently,
several combination therapies have failed to result in sig-
nificantly longer OS when compared with single agents ad-
ministered sequentially both in the pre-taxane [135, 136]
and in the taxane era [86, 137–139].
Sequential administration of CT allows us to give each
drug at its maximum tolerated dose, avoiding overlapping
toxic effects. It is possible to introduce a new drug follow-
ing disease progression or plan multicourse sequences of
CT agents without a break between the different drugs.
In a phase III trial, a combination of doxorubicin and
paclitaxel in comparison with the sequential administration
of each drug at progression (paclitaxel followed by doxo-
rubicin or vice versa) resulted in a statistically significant
higher ORR and longer TTP without differences in OS. The
QoL was similar in the three arms, even if grade 3 and 4
toxicities were inferior with the sequential schedules [86].
In two other trials using a combination of capecitabine
and taxanes with a similar design but differences in type of
trial, doses and order of sequence of the two drugs, and tax-
ane used [140, 141], a higher ORR was reported, but this
translated into a longer TTP and OS only in one trial [141].
Two phase II trials [142, 143] and three phase II ran-
domized trials [137–139] have compared combination che-
motherapy with planned sequential therapy, with no
significant differences in activity and efficacy but a better
safety profile with sequential therapy in the majority of trials.
Further indirect support to the sequential use of cyto-
toxic drugs can be derived from the results of other trials
showing that single agents were superior to combinations
because of better tolerance and similar efficacy [144, 145],
or better clinical outcome [6, 7]. Therefore, individualized
treatment is preferable and should be based on several fac-
tors, such as tumor-associated symptoms, extent of visceral
disease, comorbidities, age, and performance status. In any
case, life expectancy in this setting is relatively short, and a
gain of a few months must be balanced with treatment-
related toxicity, patient QoL, and patient preference.
At present, in the absence of specific predictive factors
to prospectively select a subgroup of responsive patients,
combination CT should be reserved for patients with rap-
idly progressing visceral metastatic disease, or in emer-
gency situations in which a rapid response is warranted.
Duration of CT
The optimal duration of CT administration in the absence of
PD is not well defined. A meta-analysis [146] of three trials
comparing a shorter with a longer duration of the same CT
in women with MBC [147–149] indicated a statistically sig-
nificant but modest survival advantage for those random-
ized to the longer duration. These data were confirmed by a
fourth trial published shortly thereafter [150]. Small incre-
ments in survival duration have a high value for women
with MBC [151]; however, these advantages must be
weighed against the additional subjective toxicity of con-
tinued CT. QoL was measured in only one of these trials
[147], and was better in patients receiving longer CT. In
contrast, longer therapy resulted in no significant differ-
ences in OS and in a slight reduction in mean quality-
adjusted survival time in another randomized trial
conducted by the European Organization for Research and
Treatment of Cancer Breast Cancer Group [152]. A signif-
icantly longer TTF was reported in patients continuing the
treatment, but this was 2 months. It should be noted that
all these studies were conducted in the pre-taxane era. Be-
cause the tolerability of these “new” drugs is different from
previously used ones, as well as dose limiting, other strate-
gies are being evaluated or need to be investigated in an at-
tempt to maintain response or stabilization of disease.
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Examples include metronomic therapies, biological agents,
and ET in patients with HR-positive tumors.
BIOLOGICAL THERAPIES
With the growing understanding of the biology of BC and
the advent of new techniques, such as genomics and pro-
teomics, multiple new targets for anticancer therapy have
been identified. These molecules are implicated in several
pathways relevant to the biology of the BC cell, such as the
signal transduction pathway, the cell cycle, the apoptotic
pathway, and the angiogenesis/metastasis pathway. To
date, the only biological agent approved in Europe for the
treatment of MBC is trastuzumab, a humanized monoclonal
antibody directed against the external domain of HER-2.
Trastuzumab
The efficacy of trastuzumab is highly dependent on the
HER-2 status of the tumor, and its benefits are only ob-
served in patients with HER-2–positive tumors, defined as
a 3 overexpression score by immunohistochemistry
(IHC) or gene amplification by fluorescence in situ hybrid-
ization (FISH). In HER-2–positive pretreated MBC pa-
tients, single-agent trastuzumab yielded an ORR of 18%
[153] that increased to 35% if it was used as first-line ther-
apy [154]. In HER-2–positive untreated MBC patients, the
addition of trastuzumab to CT resulted in a higher ORR and
longer duration of response, TTP, and OS time in compar-
ison with CT alone [8]. The longer OS time was particularly
noteworthy, considering that approximately 66% of pa-
tients treated with CT alone had received trastuzumab at the
time of PD. The combination of trastuzumab and taxanes,
paclitaxel, and more recently docetaxel [155], is the one
recommended; this is a result of the quite high incidence of
cardiac dysfunction reported with the association of trastu-
zumab and anthracycline-based regimens.
Several other single agents have been successfully com-
bined with trastuzumab in phase II trials and include weekly
paclitaxel [156], weekly [157] or three-weekly [158] do-
cetaxel, vinorelbine [159 –161], gemcitabine [162, 163],
capecitabine [164, 165], liposomal doxorubicin [166, 167],
and cisplatin [168]. Combinations of two cytotoxic agents
and trastuzumab are also being evaluated and, so far, better
results have been reported in randomized trials with the as-
sociation of paclitaxel/carboplatin and trastuzumab [169]
or platinum salts/docetaxel and trastuzumab [170], in com-
parison with regimens with a taxane and trastuzumab.
Despite the impressive results obtained with trastu-
zumab, about 50% of patients with HER-2–positive MBC
will not benefit from this agent, and the median duration of
response is between 9 and 12 months. Therefore, both de
novo and acquired resistance to trastuzumab occurs, and
other factors, besides HER-2 expression, must be involved
in the response to this agent [171].
HER-2 overexpression has been associated with pre-
clinical and clinical resistance to ET, particularly tamoxifen
[172–175]. A meta-analysis based on 12 studies and 2,379
patients showed a high correlation between retrospectively
assessed HER-2 overexpression and ET failure (tamoxifen
or other agents) that was even higher when the few ER-
negative patients were excluded [175]. Controversial re-
sults have been reported with AIs [176–178]. Significant
preclinical evidence suggests that intensive crosstalk be-
tween HER-2 and ER occurs in BC cells and there is a ra-
tionale to combine trastuzumab with antiestrogens [179];
this is being evaluated in an ongoing clinical trial. Even
though the data regarding the importance of the interactions
between the two pathways in patients treated with AIs are
less clear, several trials are examining the potential of com-
bining trastuzumab with these agents.
The most common schedule of administration of trastu-
zumab is a weekly i.v. infusion; however, because this drug
has a long half-life of approximately 28 days, an alternate
3-weekly dosing regimen has been studied as monotherapy
[180] or in combination with 3-weekly paclitaxel [181].
Further refinements to the trastuzumab schedule of admin-
istration are currently under evaluation, specifically with
respect to the impact of a loading dose. Trastuzumab is
commonly administered until PD, because a significant CB
has been demonstrated in clinical trials with such designs.
However, preclinical data and retrospective studies suggest
a rationale for using trastuzumab beyond PD in combina-
tion with different cytotoxic agents [92, 182, 183]. Two
randomized phase III trials are ongoing to try to prove this
hypothesis: the MD Anderson Cancer Center trial with vi-
norelbine and a German study with capecitabine. In partic-
ular, when the central nervous system (CNS) is the only site
of progression and systemic disease is otherwise well con-
trolled, it seems logical to continue trastuzumab while ap-
propriately managing the CNS metastasis.
Trastuzumab is quite well tolerated, with the exception
of hypersensitivity reactions seen mainly with the first in-
fusion. The only worrying side effect is the development of
cardiac dysfunction [184] reported in about 4% of patients
when trastuzumab is used alone, but increasing to 13% if
combined with paclitaxel, and to 27% with anthracyclines.
Trastuzumab-induced congestive heart failure is usually
successfully treated with standard treatment and is not dose
dependent, and the recovery from symptoms occurs even if
the drug is continued [185, 186]. Age 60 and the associ-
ation with a “classic” anthracycline were the only statisti-
cally significant predictive factors of cardiac toxicity.
There are still several undefined issues regarding the
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clinical use of trastuzumab. These include (a) the optimal
method and timing for HER-2 status assessment; (b) the op-
timal schedule of trastuzumab administration, dose, and du-
ration; (c) the mechanism of cardiotoxicity; and (d) the
emergence of resistance. Based on the available data, the
key messages for the treatment of HER-2–positive MBC
are: (a) early use of trastuzumab alone or in combination
with cytotoxic agents, according to patient and tumor char-
acteristics and previous treatments; (b) careful cardiac
monitoring of left ventricular ejection fraction by multi-
gated acquisition (MUGA) scanning or echocardiography,
currently recommended every 3 months [187]; (c) special
attention to CNS symptoms/signs, because of the propen-
sity for brain metastasis in these patients, even with a stable
or responding peripheral tumor burden [188–190].
With the increasing use of trastuzumab in the adjuvant
setting, we are facing now a new issue—the treatment of
patients who relapse while receiving or after treatment with
trastuzumab. For these patients, it is possible to restart treat-
ment with trastuzumab plus CT, but new drugs to overcome
this resistance are needed.
Lapatinib
Lapatinib is an oral, selective and highly potent dual com-
petitive inhibitor of HER-1 and HER-2 tyrosine kinases
[191]. Recently, a phase III trial evaluated the administra-
tion of capecitabine with or without lapatinib in the treat-
ment of 321 patients with HER-2–positive locally advanced
BC or MBC refractory to trastuzumab (study EGF 100151).
The median TTP in the combination arm (oral lapatinib,
1,250 mg, plus capecitabine, 2,000 mg/m2/d on days 1–14
every 3 weeks) was higher than that in the capecitabine
alone (2,500 mg/m2/d on days 1–14 every 3 weeks) arm
(36.9 weeks versus 19.7 weeks; p .001; HR 0.51, CI
0.35–0.74) without major increases in toxicity [192]. Also
noteworthy is the modest but clear activity of lapatinib
against brain metastasis, shown in 38 heavily pretreated
women with CNS progression or relapse, all previously ex-
posed to trastuzumab (5.1% RR). In addition, eight patients
showed CNS stabilization at 8 weeks and four at 24 weeks
of treatment [193].
The main toxicities observed with lapatinib are diar-
rhea, skin rash, nausea, and fatigue. An ongoing random-
ized trial is evaluating the activity of lapatinib alone or in
combination with weekly trastuzumab in patients refractory
to trastuzumab.
This agent is the most advanced in terms of clinical de-
velopment and has a favorable safety profile. Its promising
activity in advanced breast cancer makes it the ideal candi-
date for testing in the adjuvant setting. Accordingly, the
Breast International Group will soon launch two important
trials evaluating lapatinib in the neoadjuvant (450 patients)
and adjuvant (8,000 patients) settings.
Bevacizumab
Tumor growth depends upon angiogenesis, and cancer cells
begin to promote this process early in tumorigenesis. This
angiogenic impulse is characterized by oncogene-driven tu-
mor expression of proangiogenic proteins, including vascu-
lar endothelial growth factor (VEGF). VEGF is an
attractive target for antiangiogenic therapy because its re-
ceptors are present almost exclusively on genetically stable,
non-neoplastic endothelial cells, and are upregulated in tu-
mor vessels when compared with normal endothelium.
Bevacizumab (recombinant humanized monoclonal an-
tibody [rHumAb]-VEGF) is a recombinant, humanized
monoclonal antibody directed against VEGF. In a random-
ized phase III trial, bevacizumab combined with capecitab-
ine produced a significantly greater ORR in comparison
with capecitabine alone, but had no impact on PFS or OS in
pretreated MBC patients [194]. Conversely, interesting re-
sults have recently been reported in untreated MBC patients
with bevacizumab combined with weekly paclitaxel
(ECOG 2100) [195]. This combination has produced a sig-
nificantly greater ORR and longer PFS time in comparison
with weekly paclitaxel alone. As expected, higher inci-
dences of hypertension requiring treatment, bleeding, grade
3 or 4 proteinuria, and neuropathy were observed in the be-
vacizumab arm. A statistically nonsignificant advantage in
OS has also been observed even though the median OS time
has just been reached. One criticism of this study is related
to the low ORR observed in the control arm, which could be
a result of the weekly schedule used, the dose selected, or
patient selection.
Therefore, although very intriguing, these data need to
be confirmed in other randomized trials. The different re-
sults observed in these two bevacizumab trials might be ex-
plained by the important differences in patient population.
In the ECOG 2100 trial, all patients received the combina-
tion as first-line therapy for MBC, while in the capecita-
bine/bevacizumab trial, 84.9% of patients had previously
received CT for MBC, mostly anthracyclines and taxanes.
This could suggest that antiangiogenic agents should be
given early in the course of disease.
An additional problem surrounding bevacizumab is the
lack of valid predictive factors that can help to select pa-
tients most likely to benefit from this agent. Additionally,
some studies have failed to show any predictive value of
urine VEGF and vascular cell adhesion molecule
(VCAM)-1 [195]. For this reason, some experts refer to be-
vacizumab as “a targeted therapy without a target.”
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CONCLUSIONS AND FUTURE PERSPECTIVES
The achievements obtained in MBC treatment in the so-
called pregenomic era have been impressive and have led to
longer PFS and OS times. The median survival time in pa-
tients with MBC has increased significantly in the last de-
cade from 438 days during the years 1991–1992 to 667 days
in 1999–2001 [196]. Randomized trials have been funda-
mental in helping us to select our treatment strategies, but
the aim of MBC therapy is still essentially palliative and fo-
cused on improving QoL.
Tamoxifen, the gold standard ET for decades, has been
replaced by the third-generation AIs as first-line ET for the
majority of postmenopausal patients with endocrine-re-
sponsive disease, but we still do not know the best strategy
for subsequent lines of treatment. Furthermore, a better un-
derstanding of the mechanisms of resistance to endocrine
agents is necessary. For patients with endocrine nonrespon-
sive disease, the use of anthracyclines and taxanes has
changed the way we treat metastatic patients, but with their
wider use in the adjuvant setting new standards of care are
needed. Several drugs have shown activity after the failure
of these agents, such as capecitabine, vinorelbine, and gem-
citabine, but new drugs with different mechanisms of action
and new combinations are eagerly waited.
HER-2–positive BC should be considered a separate en-
tity and treated accordingly. The use of trastuzumab in pa-
tients with HER-2–overexpressing tumors has changed the
natural history of this disease and can probably be consid-
ered the most important achievement to date in the treat-
ment of BC.
There are still many unanswered questions and new
drugs are under evaluation.
The scarcity of agreement on standards of care renders
the treatment of MBC complex. Furthermore, this disease
requires a multidisciplinary team approach, with the early
involvement of psychosocial support and palliative inter-
ventions as part of routine patient care. Patients must be en-
couraged to be actively involved in the treatment decision-
making process; and their enrolment in well-designed trials
is highly recommended.
With the development of new technologies, namely
genomics and proteomics, we are aware that BC is not just
a single entity but a complex disease with considerable mo-
lecular diversity that often translates into different clinical
phenotypes. A better definition of these subtypes will prob-
ably change our treatment approach, moving from the era of
empirically based treatment to the era of tailored therapies
for each individual patient.
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